ABSTRACT
Objective To systematically evaluate the clinical effect and safety of repaglinide and metformin for treating diabetes mellitus (MD) of secondary failure of sulfonylurea (SFS).Methods The randomized controlled trials (RCT) at home and abroad on the comparison of effect and safety of repaglinide and metformin in treating MD with SFS were retrieved.The modified Jadad scale was employed to evaluate the literature quality.The RevMan5.3.1 software was used for conducting the meta analysis.Results A total of 10 RCT were included.The meta-analysis results showed that compared with metformin for treating MA with SFS,repaglinide decreased the fasting blood glucose effectively (MD=-2.30,95 ％ CI:-2.53--2.06,P＜0.01),increased the fasting C-peptide (MD=0.06,95％CI:0.02-0.11,P=0.01),reduced the postprandial 2 h blood glucose (MD=-2.17,95 ％CI:-2.44-1.89,P＜0.01) and decreased glycosylated hemoglobin (MD=-2.60,95％CI:-3.21--2.00,P＜0.01) as well as the adverse reactions (RR=0.05,95％CI:0.02-0.09,P＜0.01).However,there was no statistical difference in fasting insulin between the repaglinide and metformin groups (MD=0.18,95％CI:-0.18-0.54,P=0.32).Conclusion Currently evidences suggest that repaglinide is superior to metformin for treating MD with SFS.
ABSTRACT
Objective: To compare the curative effect of Fritillariae Cirrhosae Bulbus (FCB) in six species from five origins on recurrent asthma in mice. Methods: Eighty one female Kunming mice were randomly divided into nine groups with equal weights, such as model, control, Dexamethasone (DEX, positive control), and six FCB groups. The mice in the model, DEX, and FCB groups were sc injected with ovalbumin (OVA) on days 1, 7, and 14, then challenged with the aerosols of normal saline contained OVA on days 22-28. The mice in DEX and FCB groups were ig administered with DEX (0.6 mg/kg) and FCB (830 mg/kg) respectively for 28 d, and the mice in the control group were given 0.1% carboxymethyl cellulose. The surface tension of bronchoalveolar lavage was measured, the lung tissues were taken for hematoxylin-eosin (HE) staining, and the tracheal stenosis and volume difference of pulmonary alveolus were analyzed by the microphotograph. Results: Compared with the control group, the tracheal stenosis, surface tension, and volume difference of pulmonary alveolus were increased obviously in the model group (P < 0.01). The pathological section revealed vessel wall thickening in bronchiole, inflammatory cell infiltrating, gland hyperplasia, and mucus hypersecretion, but FCB could reverse these pathological changes (P < 0.01). Each FCB had its feature to cure asthma. F. unibracteata and F. delavayi had the most potency on increasing alveolar surfactant; F. unibracteata and F. taipaiensis had the most potency on attenuating tracheal stenosis; F. unibracteata and F. przewalskii had the most potency on relieving the inflammation; F. unibracteata and F. taipaiensis had the most potency on reducing glandular hyperplasia or intimal thickening. Each FCB had its feature to cure asthma, but F. unibracteata was the best. Conclusion: FCB has the best potency to prevent and cure the recurrent asthma in mice, but each FCB has its feature. The diversity of FCB species should be protected.